Viagra (Sildenafil): Complete Drug-Drug Interaction Profile

How Sildenafil Works: The PDE5-cGMP Pathway

Sildenafil selectively inhibits phosphodiesterase type 5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in corpus cavernosum smooth muscle. When a man is sexually stimulated, nitric oxide is released from cavernosal nerve terminals and endothelial cells, activating guanylate cyclase to produce cGMP. Sildenafil blocks its breakdown. The result is sustained smooth muscle relaxation, increased arterial inflow, and an erection.

Goldstein et al. established the clinical proof of concept in the 1998 landmark trial (N=532 across two double-blind studies), demonstrating that sildenafil 25 to 100 mg produced successful intercourse in 69% of attempts versus 22% with placebo 1. That trial confirmed both efficacy and the hemodynamic profile that defines every interaction discussed below. Because sildenafil amplifies an existing nitric oxide signal rather than generating one, it produces modest systemic vasodilation (mean blood pressure decrease of 8.4/5.5 mmHg) even when taken alone 2. Any co-administered drug that also lowers blood pressure through nitric oxide, cGMP, or vascular smooth muscle relaxation can compound that drop. This is the pharmacological spine of the entire interaction profile.

The drug is metabolized primarily by hepatic CYP3A4 and, to a lesser extent, CYP2C9 3. Its major active metabolite, N-desmethylsildenafil, retains about 50% of PDE5 inhibitory potency and a plasma half-life of roughly 4 hours. Anything that shifts CYP3A4 activity shifts the entire exposure curve.

Nitrates: The Absolute Contraindication

Co-administration of sildenafil with any organic nitrate, in any form, is contraindicated. Period.

Nitrates donate exogenous nitric oxide, which stimulates cGMP production in vascular smooth muscle. Sildenafil then prevents cGMP degradation. The combined effect produces profound, sustained vasodilation that can drop systolic blood pressure by 40 mmHg or more. A pharmacokinetic crossover study by Webb et al. (2000) showed that 100 mg sildenafil with 0.4 mg sublingual nitroglycerin produced a mean maximal decrease in systolic pressure of 52 mmHg and diastolic of 29 mmHg 4. This interaction has caused fatalities.

The FDA label mandates a minimum 24-hour washout after sildenafil before any nitrate can be given 3. The ACC/AHA guidelines extend this to 48 hours in clinical practice for patients with coronary artery disease who may need emergent nitroglycerin 5. This applies to all nitrate formulations: sublingual nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, nitroglycerin paste, and inhaled amyl nitrite ("poppers"). Recreational amyl nitrite is a frequently missed culprit in emergency department presentations.

If a patient on sildenafil presents with chest pain, treat with non-nitrate alternatives. Beta-blockers, morphine, heparin, and aspirin remain safe. Phenylephrine can be used as a vasopressor if hypotension occurs.

Riociguat: The Other Absolute Contraindication

Riociguat (Adempas), a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, acts upstream in the same NO-cGMP pathway. It directly stimulates guanylate cyclase production of cGMP independent of nitric oxide. Combining it with a PDE5 inhibitor creates additive cGMP accumulation with unpredictable hypotension 6. The PATENT-1 trial protocol specifically excluded patients on PDE5 inhibitors, and the riociguat label carries a boxed contraindication against the combination.

There is no safe washout window defined. If a patient transitions between therapies, most pulmonology guidelines recommend a 24-hour gap after stopping sildenafil before initiating riociguat.

CYP3A4 Inhibitors: When 50 mg Behaves Like 200 mg

Because CYP3A4 is the primary metabolic route, potent inhibitors of this enzyme dramatically increase sildenafil plasma concentrations.

Strong CYP3A4 inhibitors require mandatory dose reduction to 25 mg sildenafil, and some warrant avoiding the combination entirely:

• Ritonavir (and ritonavir-boosted protease inhibitors): A single 500 mg dose of ritonavir increased sildenafil AUC by 1,100% (11-fold) in a pharmacokinetic study 7. The FDA label recommends a maximum of 25 mg sildenafil in a 48-hour period when taken with ritonavir.
• Ketoconazole / itraconazole: Ketoconazole 400 mg daily raised sildenafil AUC by 3-fold 3. Start at 25 mg.
• Clarithromycin: Expected to produce similar magnitude increases based on its CYP3A4 inhibitory potency. Use 25 mg.

Moderate CYP3A4 inhibitors produce smaller but clinically relevant increases:

• Erythromycin: Increased sildenafil AUC by 182% in a crossover study 3. Consider 25 mg starting dose.
• Diltiazem / verapamil: Both are moderate CYP3A4 inhibitors and calcium channel blockers, producing pharmacokinetic and pharmacodynamic additive effects. Start low.
• Fluconazole: Moderate inhibitor; clinical data on sildenafil are limited but dose reduction is prudent.

Grapefruit juice inhibits intestinal CYP3A4. A single glass with a single dose is unlikely to produce a clinically dangerous interaction. Repeated consumption of large quantities (more than one quart daily) could raise sildenafil exposure meaningfully 8. The practical recommendation: one glass is fine, a grapefruit habit with daily sildenafil use warrants a conversation.

CYP3A4 Inducers: When 100 mg May Not Be Enough

Strong CYP3A4 inducers accelerate sildenafil metabolism and can render standard doses ineffective:

• Rifampin: The most potent CYP3A4 inducer in clinical use. Although no published pharmacokinetic study has quantified the interaction with sildenafil specifically, rifampin reduces midazolam AUC by over 90%, and a similar magnitude of sildenafil reduction is expected 9.
• Carbamazepine, phenytoin, phenobarbital: These antiepileptics induce CYP3A4 and may require higher sildenafil doses or consideration of alternative PDE5 inhibitors with different metabolic pathways (avanafil is also CYP3A4-dependent; tadalafil is partially metabolized by CYP3A4 but has a longer half-life that may buffer the effect).
• St. John's Wort (Hypericum perforatum): A potent CYP3A4 inducer that patients often fail to disclose. Ask about it.

Patients on chronic enzyme inducers who report sildenafil "stopped working" deserve a medication reconciliation before dose escalation.

Alpha-Blockers: Manageable but Timing-Dependent

Alpha-1 adrenergic blockers, used for benign prostatic hyperplasia (BPH) or hypertension, cause additive hypotension with sildenafil because both drug classes reduce peripheral vascular resistance. The interaction is not a contraindication but requires dose separation and a cautious starting dose.

The FDA label recommends that sildenafil be initiated at 25 mg in patients on alpha-blockers and that the patient be stable on the alpha-blocker before adding sildenafil 3. Timing matters. A study of sildenafil 100 mg co-administered with doxazosin 4 mg at simultaneous dosing produced a mean additional systolic blood pressure drop of 7 mmHg standing and symptomatic hypotension in some subjects 10. Separating doses by 4 hours significantly attenuated this effect.

Tamsulosin (0.4 mg), the most commonly prescribed uroselective alpha-blocker, has a narrower interaction profile than doxazosin or terazosin due to its selectivity for alpha-1A receptors over alpha-1B (the vascular subtype). A pharmacodynamic study by Kloner et al. showed that tamsulosin 0.4 mg combined with sildenafil 100 mg produced no statistically significant orthostatic hypotension compared to sildenafil alone 11. Still, the FDA label does not exempt tamsulosin from the starting-dose precaution.

Practical guidance: start sildenafil at 25 mg, take the alpha-blocker at bedtime and sildenafil at least 4 hours later, and counsel the patient to rise slowly from seated or supine positions.

Antihypertensives: Additive but Generally Safe

Sildenafil was originally developed as an antihypertensive. Its blood pressure-lowering effect is real, consistent, and additive with every antihypertensive class.

A pooled analysis of clinical trial data showed that sildenafil 50 to 100 mg added to existing antihypertensive regimens produced a mean additional drop of 8/5 mmHg 2. Amlodipine co-administration specifically yielded an additional 8/7 mmHg supine reduction 3. For most patients with well-controlled hypertension on stable regimens, this is tolerable. For patients on three or more antihypertensives with systolic pressures already near 120 mmHg, it demands caution.

ACE inhibitors, ARBs, beta-blockers, thiazide diuretics, and calcium channel blockers are all safe to combine with sildenafil from a pharmacokinetic standpoint. The interaction is purely pharmacodynamic (additive blood pressure lowering) and manageable with monitoring.

"The blood pressure effects of sildenafil are modest and generally well-tolerated in patients on antihypertensive therapy, but individual susceptibility varies," states the ACC consensus statement on sexual activity and cardiovascular disease 5.

Alcohol: More Than a Social Concern

Ethanol is a vasodilator. Combined with sildenafil, it produces additive hypotension and reflex tachycardia. An FDA-reviewed pharmacodynamic study demonstrated that sildenafil 50 mg with ethanol 0.5 g/kg (roughly 3 to 4 drinks for a 70 kg male) produced a mean heart rate increase of 11 bpm and a standing systolic blood pressure decrease of 24 mmHg in healthy volunteers 3. The practical advice is not absolute abstinence but moderation: one to two drinks. Heavy alcohol use also independently impairs erectile function, which defeats the purpose.

Anticoagulants and Antiplatelets

Sildenafil has a mild antiplatelet effect in vitro, inhibiting platelet aggregation through the PDE5-cGMP pathway. A study by Halcox et al. demonstrated synergistic inhibition of platelet aggregation when sildenafil was combined with sodium nitroprusside 12. However, clinical bleeding studies have not shown a meaningful increase in bleeding risk when sildenafil is combined with aspirin or warfarin. The FDA label notes no significant pharmacokinetic interaction with warfarin, and no dose adjustment is required 3.

For patients on direct oral anticoagulants (apixaban, rivarelbam), note that apixaban is also a CYP3A4 substrate. There is no direct pharmacokinetic interaction with sildenafil, but both drugs competing for the same metabolic pathway in the presence of a CYP3A4 inhibitor could theoretically increase exposure to both agents.

Other Interactions Worth Knowing

Cimetidine: This H2 blocker is a weak, non-selective cytochrome P450 inhibitor. It increased sildenafil AUC by 56% in a pharmacokinetic study 3. Clinically marginal. No dose adjustment needed for most patients.

Antacids: No pharmacokinetic interaction. Sildenafil absorption is modestly delayed by a high-fat meal (Tmax shifts from 0.5 to 1.5 hours), but total bioavailability is preserved.

Bosentan: This endothelin receptor antagonist and moderate CYP3A4 inducer reduces sildenafil AUC by approximately 63% with chronic co-administration 13. Relevant primarily in pulmonary arterial hypertension, where sildenafil (as Revatio 20 mg TID) and bosentan are sometimes combined. Dose adjustments may be necessary.

SSRIs and SNRIs: No direct pharmacokinetic interaction, but SSRIs cause sexual dysfunction in 30 to 70% of users 14. Sildenafil may partially counteract SSRI-induced erectile dysfunction, and the combination is safe from a drug interaction standpoint.

"When prescribing PDE5 inhibitors for SSRI-associated sexual dysfunction, clinicians should set expectations clearly: sildenafil can improve erectile function but will not reverse SSRI-related anorgasmia or decreased libido," notes the Endocrine Society clinical practice guideline on testosterone therapy 15.

Dose Adjustment Summary by Interaction

A quick reference for the clinician writing the prescription:

• Nitrates: Contraindicated. No safe dose.
• Riociguat: Contraindicated. No safe dose.
• Ritonavir: Maximum 25 mg in 48 hours.
• Ketoconazole/itraconazole: Start at 25 mg.
• Erythromycin/clarithromycin: Start at 25 mg.
• Alpha-blockers: Start at 25 mg; separate dosing by 4 hours.
• Stable antihypertensives: No dose adjustment; monitor BP.
• CYP3A4 inducers (rifampin, carbamazepine): May need higher doses; evaluate response.
• Hepatic impairment (Child-Pugh A/B): Start at 25 mg due to reduced clearance.
• Age over 65: Start at 25 mg (reduced clearance, mean AUC 40% higher) 3.
• Renal impairment (CrCl <30 mL/min): Start at 25 mg.